---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-035248"
form_type: "8-K"
ticker: "STSS"
cik: "0001737995"
company_name: "Sharps Technology Inc."
filed_at: "2022-12-13T23:59:59+00:00"
generated_at: "2026-06-21T05:33:34.197389+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Sharps Technology enters exclusive U.S. distribution agreement with Nephron Pharmaceuticals for syringe products

## Summary
- Distribution agreement appoints Nephron as exclusive U.S. distributor for Sharps' syringe products.
- First products expected available by end of January 2023; initial revenue anticipated in first half of 2023.
- Agreement supports previously announced Inject-EZ startup in South Carolina, expected to begin in early 2023.
- Two-year term, with 30-day termination notice by either party for any reason.
- Nephron's sales network includes over 3,000 customers via direct and online channels.

## SEC filing metadata
- accession: 0001493152-22-035248
- form_type: 8-K
- ticker: STSS
- cik: 0001737995
- company_name: Sharps Technology Inc.
- filed_at: 2022-12-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737995/000149315222035248/0001493152-22-035248-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737995/000149315222035248/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-035248
- JSON: https://secwatch.observer/filing/0001493152-22-035248.json
- Plain text: https://secwatch.observer/filing/0001493152-22-035248.txt

## Key facts
- Material Agreements
  Sharps Technology Inc. entered into Distribution Agreement with Nephron Pharmaceuticals Corporation and Nephron SC, Inc. (collectively, "Nephron") (effective 2022-12-08).
  - Action: entry
  - Agreement: supply
  - Counterparty: Nephron Pharmaceuticals Corporation and Nephron SC, Inc. (collectively, "Nephron")
  - Effective: 2022-12-08
  source text: On December 8, 2022, Sharps Technology, Inc. (the “Company”) entered into a distribution agreement (the “Distribution Agreement”) with Nephron Pharmaceuticals Corporation and Nephron SC, Inc. (collectively, “Nephron”), pursuant to which the Company appointed Nephron as its exclusive distributor for the sale and distribution of the products subject to the Distribution Agreement in and throughout the United States.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737995/000149315222035248/0001493152-22-035248-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.